See more : Establishment Labs Holdings Inc. (ESTA) Income Statement Analysis – Financial Results
Complete financial analysis of Paragon 28, Inc. (FNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paragon 28, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- ALX Resources Corp. (AL.V) Income Statement Analysis – Financial Results
- Xilinx, Inc. (0M1U.L) Income Statement Analysis – Financial Results
- Butterfly Network, Inc. (BFLY-WT) Income Statement Analysis – Financial Results
- Leong Hup International Berhad (6633.KL) Income Statement Analysis – Financial Results
- Canara Bank (CANBK.NS) Income Statement Analysis – Financial Results
Paragon 28, Inc. (FNA)
About Paragon 28, Inc.
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 216.39M | 181.38M | 147.46M | 110.98M | 106.28M |
| Cost of Revenue | 51.95M | 32.46M | 28.02M | 25.10M | 18.83M |
| Gross Profit | 164.44M | 148.93M | 119.44M | 85.88M | 87.45M |
| Gross Profit Ratio | 75.99% | 82.11% | 81.00% | 77.38% | 82.28% |
| Research & Development | 30.08M | 24.65M | 16.13M | 11.17M | 10.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.02M | 159.32M | 114.09M | 72.64M | 74.44M |
| Other Expenses | 0.00 | -1.21M | -486.00K | 3.56M | -98.00K |
| Operating Expenses | 210.10M | 183.97M | 130.22M | 83.81M | 84.73M |
| Cost & Expenses | 262.05M | 216.43M | 158.24M | 108.91M | 103.56M |
| Interest Income | 0.00 | 4.13M | 1.72M | 602.00K | 648.00K |
| Interest Expense | 5.17M | 4.13M | 1.72M | 602.00K | 648.00K |
| Depreciation & Amortization | 15.54M | 13.73M | 8.96M | 6.38M | 4.20M |
| EBITDA | -36.61M | -47.86M | -2.30M | 12.01M | 6.82M |
| EBITDA Ratio | -16.92% | -12.42% | -1.56% | 10.82% | 6.42% |
| Operating Income | -45.67M | -35.05M | -10.78M | 5.63M | 2.72M |
| Operating Income Ratio | -21.10% | -19.32% | -7.31% | 5.07% | 2.56% |
| Total Other Income/Expenses | -11.66M | -5.34M | -2.21M | 2.96M | -746.00K |
| Income Before Tax | -57.32M | -67.39M | -12.98M | 5.03M | 1.97M |
| Income Before Tax Ratio | -26.49% | -37.15% | -8.80% | 4.53% | 1.85% |
| Income Tax Expense | 213.00K | -64.00K | 713.00K | 1.53M | -1.15M |
| Net Income | -57.53M | -67.33M | -13.69M | 2.69M | 3.12M |
| Net Income Ratio | -26.59% | -37.12% | -9.29% | 2.42% | 2.93% |
| EPS | -0.70 | -0.88 | -0.18 | 0.04 | 0.04 |
| EPS Diluted | -0.70 | -0.88 | -0.18 | 0.04 | 0.04 |
| Weighted Avg Shares Out | 82.09M | 76.77M | 76.45M | 76.37M | 76.37M |
| Weighted Avg Shares Out (Dil) | 82.09M | 76.77M | 76.45M | 76.37M | 76.37M |
Levi & Korsinsky Reminds Paragon 28, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 29, 2024 - FNA
FNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Paragon 28, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Paragon 28, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 29, 2024 to Discuss Your Rights - FNA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 29, 2024 in Paragon 28, Inc. Lawsuit - FNA
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Paragon 28, Inc. - FNA
Class Action Filed Against Paragon 28, Inc. (FNA) - November 29, 2024 Deadline to Join - Contact Levi & Korsinsky
Levi & Korsinsky Reminds Paragon 28, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 29, 2024 - FNA
Paragon 28, Inc. Is Being Sued For Violating Securities Regulations And The Schall Law Firm Invites Investor Participation
Paragon 28, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 29, 2024 to Discuss Your Rights - FNA
Investors who Lost Money on Paragon 28, Inc. (FNA) Should Contact Levi & Korsinsky About Pending Class Action - FNA
Source: https://incomestatements.info
Category: Stock Reports